|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Division of Hematology, Barnes-Jewish Hospital
at Washington University Medical Center, St Louis, MO.
Protein Z-dependent protease inhibitor (ZPI) is a 72-kd
member of the serpin superfamily of proteinase inhibitors that produces rapid inhibition of factor Xa in the presence of protein Z (PZ), procoagulant phospholipids, and Ca++ (t1/2 less
than 10 seconds). The rate of factor Xa inhibition by ZPI is reduced
more than 1000-fold in the absence of PZ. The factor Xa-ZPI complex is
not stable to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, but is detectable by alkaline-polyacrylamide gel
electrophoresis. The combination of PZ and ZPI dramatically delays the
initiation and reduces the ultimate rate of thrombin generation in
mixtures containing prothrombin, factor V, phospholipids, and
Ca++. In similar mixtures containing factor Va, however, PZ
and ZPI do not inhibit thrombin generation. Thus, the major effect of PZ and ZPI is to dampen the coagulation response prior to the formation
of the prothrombinase complex. Besides factor Xa, ZPI also inhibits
factor XIa in the absence of PZ, phospholipids, and Ca++.
Heparin (0.2 U/mL) enhances the rate (t1/2 = 25 seconds
vs 50 seconds) and the extent (99% vs 93% at 30 minutes) of
factor XIa inhibition by ZPI. During its inhibitory interaction with
factor Xa and factor XIa, ZPI is proteolytically cleaved with
the release of a 4.2-kd peptide. The N-terminal amino acid
sequence of this peptide (SMPPVIKVDRPF) establishes Y387 as the
P1 residue at the reactive center of ZPI. ZPI activity is
consumed during the in vitro coagulation of plasma through a
proteolytic process that involves the actions of factor Xa with PZ
and factor XIa.
(Blood. 2000;96:3049-3055) Vitamin K is required for the post-translational
formation of a unique amino acid, gamma-carboxyglutamic acid (Gla),
which is present in a number of plasma proteins that are involved in hemostasis.1,2 Gla-mediated Ca++ binding in
these proteins is necessary for their association with phospholipid
surfaces and is critical for their hemostatic function.3
Protein Z (PZ) is a 62-kd vitamin K-dependent plasma protein
whose structure is very similar to coagulation factors VII, IX, and X
and protein C. In contrast to these serine protease zymogens, however,
in PZ the region around the typical activation site is absent, and the
histidine and serine residues of the canonical catalytic triad are
missing.4,5 The plasma half-life of PZ is approximately
2.5 days, and plasma PZ levels in blood donors span a broad range, with
a mean of 2.9 ± 1.0 µg/mL in EDTA-anticoagulated samples.6 PZ was noted to differ from the other vitamin
K-dependent coagulation factors in 2 important respects: (1) markedly
slower association and dissociation rates with/from phospholipid
vesicles7; and (2) a dramatic reduction in the plasma PZ
level with warfarin therapy.6 Although bovine PZ was
isolated in 1977 and human PZ was isolated in
1984,8,9 the function of PZ remained uncertain.
In more recent studies, it was found that the procoagulant activity of
factor Xa in a one-stage plasma coagulation assay was reduced when
factor Xa was first incubated with PZ. This apparent inhibitory effect
was time-dependent (maximal by 90 to 120 seconds) and required the
presence of Ca++ and procoagulant
phospholipids.10 The time dependence was related predominantly to the incubation period of PZ with phospholipid, probably reflecting the relatively slow rate of PZ's association with
phospholipid.7 PZ that was proteolytically cleaved at R-43
(single-letter amino acid code), thereby separating its Gla domain from the remainder of the molecule, lacked inhibitory
activity.10 These results suggested that an interaction
between factor Xa and PZ occurs at the phospholipid surface. Consistent
with this notion, the rate of inhibition of factor Xa by antithrombin
was slowed by PZ in the presence of phospholipids and
Ca++.10 Additional work showed that the
inhibitory effect of PZ on factor Xa activity in the one-stage
coagulation assay was due at least in part to a previously unidentified
plasma proteinase inhibitor that recognizes the factor Xa-PZ complex.
Protein Z-dependent protease inhibitor (ZPI) is an approximately
72-kd member of the serpin superfamily of proteinase
inhibitors.11 In the presence of PZ, procoagulant
phospholipids, and Ca++, ZPI produces rapid inhibition of
factor Xa (t1/2 less than 10 seconds) in a process that
appears to involve the formation of a Ca++-dependent
tertiary complex containing factor Xa, PZ, and ZPI at the phospholipid
surface.10 Northern analysis of tissues suggests that a
major site of ZPI synthesis is the liver.11 On the basis
of studies of the inhibitory activity of an altered form of recombinant
ZPI, Y387 is thought to be the P1 residue at the reactive
center of ZPI.11 Initial investigations of the inhibitory
spectrum of ZPI failed to identify a proteinase besides factor Xa that
was inactivated by ZPI in the presence or absence of PZ.
The presence of PZ delays the initiation and reduces the ultimate
extent of thrombin generation in plasma induced to clot by low
concentrations of factor IXa.12 PZ null mice have an apparently normal phenotype, but PZ deficiency dramatically increases the severity of the thrombotic phenotype of mice carrying the factor
VLeiden genotype.12 These in vitro and in vivo
studies suggest that PZ plays an important role in dampening
coagulation. Presumably the cofactor effect of PZ for the
inactivation of factor Xa by ZPI is an important part of this
regulatory action of PZ. Here we report experiments designed to further
characterize the properties of ZPI.
Materials
Proteins
Antibodies and ZPI immunoassay Rabbit polyclonal anti-ZPI antibodies have been previously described.10 Rabbit polyclonal antibodies against a peptide representing the N-terminal sequence of the ZPI molecule (residues 1 through 14, LAPSPQSPETRAPQ were produced as previously described.14 Mouse monoclonal anti-ZPI antibodies were produced by means of established and previously reported techniques6 and conjugated with biotin with the use of EZ-Link Sulfo-NHS-LC-Biotin (Pierce; Rockford, IL) as described by the manufacturer. For ZPI immunoassay, 150 µL of rabbit anti-ZPI polyclonal antibodies (20 µg/mL) in 0.1 mol/L NaCl, 0.05 mol/L Hepes, pH 7.4 (HS), was incubated overnight at room temperature in the well of a microtiter plate (Nunc, Fisher Scientific; Hanover Park, IL). After the wells were washed with phosphate-buffered saline containing 0.05% Tween 20 (PBST) (200 µL, 4 ×), samples (150 µL) diluted in PBST were applied to the wells and allowed to incubate 1 hour. After washing the wells with PBST, a solution (150 µL) containing biotin-conjugated anti-ZPI monoclonal antibodies MC4249.2 (2 µg/mL) and MC4249.3 (2 µg/mL) in HS with 1 mg/mL bovine serum albumin (HSA) was added to each well and incubated for 1 hour. The wells were washed with PBST, and 150 µL of a 1:100 dilution of streptavidin-horseradish peroxidase complex (Pierce) in PBST was applied. After 1 hour, the wells were washed with PBST, and 200 µL of TMB liquid substrate was added. After exactly 5 minutes, 100 µL 0.5 mol/L H2SO4 was added to stop the reaction, and the A450 was measured by means of a Vmax microtiter plate reader (Molecular Devices; Sunnyvale, CA). Purified ZPI produced a linear dose response in this assay at concentrations of 0 to 15 ng/mL; pooled plasma was tested at 1:200 and 1:400 dilutions. ZPI concentration of the standard was determined by amino acid composition (Protein Chemistry Laboratory, Washington University, St Louis, MO).Factor Xa inhibition by ZPI Mixtures containing factor Xa (5 nmol/L), CaCl2 (4 mmol/L), phospholipids (15 µmol/L) with or without PZ (40 nmol/L) were constructed at room temperature in HSA, and the reaction was initiated by the addition of ZPI (69 nmol/L). At various times thereafter, samples were removed from the mixtures and diluted in HSA, and the remaining factor Xa activity was determined by coagulation assay.10 To evaluate the effect of heparin on factor Xa inhibition by ZPI in the absence of PZ, ZPI (42 nmol/L) was added to mixtures containing factor Xa (1.5 nmol/L), CaCl2 (4 mmol/L), phospholipids (15 µmol/L), with or without heparin (0.25 U/mL), at room temperature. After 1 hour, Spectrazyme Xa (200 µmol/L) was added, and remaining factor Xa was determined as amidolytic activity and compared with a factor Xa standard curve. Owing to the rapid inhibition of factor Xa produced by ZPI in the presence of PZ, the effect of heparin on the inhibition of factor Xa by ZPI in the presence of PZ was tested by examining the progress curve (A405) of factor Xa inhibition in the presence of Spectrazyme Xa (250 µmol/L).Factor Xa-ZPI complex on alkaline-polyacrylamide gel electrophoresis Mixtures containing phospholipids (15 µmol/L) and CaCl2 (4 mmol/L), with various combinations of factor Xa (10 nmol/L), PZ (32 nmol/L), and ZPI (28 nmol/L), were incubated at room temperature. After 2 minutes, 10 µL samples were separated by 8% alkaline-polyacrylamide gel electrophoresis (alkaline-PAGE) for 90 minutes at 120 V and analyzed by Western blotting with the use of goat anti-factor X antibodies (Enzyme Research Laboratories) and chemiluminescence detection.11,15,16Inhibition of thrombin generation by ZPI Mixtures containing PZ (40 nmol/L), ZPI (69 nmol/L), phospholipids (15 µmol/L), CaCl2 (4 mmol/L), and factor V (6 nmol/L) or factor Va (6 nmol/L) in HSA were incubated 2 minutes at room temperature. Prothrombin (1.4 µmol/L) and factor Xa (0.1 nmol/L) were then added in succession to initiate the reaction. Samples were removed at various times and diluted with HSA containing 10 mmol/L EDTA, and the thrombin concentration was determined as amidolytic activity against S2238 (200 µmol/L) in comparison with a standard curve constructed with purified thrombin. In certain experiments, factor Xa was included with other reactants during the initial 2-minute incubation, and the reaction was initiated by the addition of prothrombin.Reversibility of ZPI-mediated factor Xa inhibition Mixtures containing factor Xa (20 nmol/L), phospholipids (25 µmol/L), CaCl2 (5 mmol/L), with and without factor Va (30 nmol/L) and with and without PZ (80 nmol/L) and ZPI (56 nmol/L), were constructed in HS. After 3 minutes at room temperature, a one-tenth volume of EDTA (100 mmol/L) or HS was added, and the mixtures were transferred to a 37° water bath. At various times thereafter, samples were removed for Western blot analysis with rabbit anti-ZPI antibodies and factor Xa coagulation assay following dilution.10ZPI inhibition of factor XIIa, kallikrein, and factor XIa Proteinases were incubated with or without ZPI (35 nmol/L) at room temperature in the presence or absence of PZ (40 nmol/L), phospholipids (15 µmol/L), and CaCl2 (4 mmol/L). After 15 minutes, remaining proteinase activity was determined by amidolytic assay. The tested proteinases and their respective chromogenic substrates were as follows: factor XIIa (12.5 nmol/L), S2302 (130 µmol/L); kallikrein (8.1 nmol/L), S2302 (400 µmol/L); and factor XIa (2.5 nmol/L), S2366 (1 mmol/L). In experiments to further examine the inhibition of factor XIa by ZPI, mixtures were constructed containing factor XIa (1 nmol/L), with or without HK (0.5 µmol/L) and with or without heparin (0.20 U/mL), and the inhibitory process was initiated with the addition of ZPI (69 nmol/L). At various times thereafter, samples were removed, and residual factor XIa activity was determined by the addition of S2366 (250 µmol/L) and comparison of the amidolytic activity with a factor XIa standard curve.Isolation and amino acid sequencing of the ZPI proteolytic fragments produced by factors Xa and XIa A mixture containing factor Xa (3.6 µmol/L), ZPI (5.56 µmol/L), PZ (4.84 µmol/L), CaCl2 (4 mmol/L), and phospholipids (150 µmol/L) and a mixture containing factor XIa (1 µmol/L) and ZPI (5.56 µmol/L) in HS were incubated at 37°C. After 1 hour, 50 µL samples were separated by 10% to 20% gradient sodium dodecyl sulfate (SDS)-PAGE by means of a tricine/glycine buffer system (Bio-Rad Laboratories) and electrotransferred onto a polyvinylidene fluoride membrane (Micron Separations, Inc; Westborough, MA) in 10 mmol/L CAPS, pH 11.0, 10% (vol/vol) methanol. The membrane was stained with 0.025% (wt/vol) Coomassie Brilliant Blue R-250 in 40% methanol for 5 minutes and then destained with 50% methanol for 10 minutes. The membrane was rinsed several times with distilled water and allowed to air dry. The discernible 4.2 kd-protein bands were cut from the membrane, and their N-terminal amino acid sequences determined by the Protein Chemistry Laboratory.Proteolysis of ZPI during coagulation in plasma Coagulation was induced in normal and various factor-deficient citrated plasmas (George King Biomedical) by the addition of a one-tenth volume of human brain thromboplastin with CaCl2 (250 mmol/L); the addition of a one-tenth volume of freshly prepared 1% (wt/vol) kaolin, phospholipids (200 µmol/L), and CaCl2 (250 mmol/L); or the addition of a one-tenth volume of crude Taipan snake venom (10 µg/mL), phospholipids (200 µmol/L), and CaCl2 (250 mmol/L). In certain experiments, plasmas were treated with kaolin alone. The mixtures were incubated for 30 minutes at 37°C and centrifuged (10 000g, 5 minutes) to separate the fibrin pellet from the serum. In additional experiments, a one-tenth volume of XCP from Russell's Viper venom (1.0 µg/mL), phospholipids (200 µmol/L), and CaCl2 (150 mmol/L) was used to induce coagulation in barium-adsorbed plasma12 that had been supplemented with factor X (8 µg/mL) and PZ (10 µg/mL). ZPI in plasma and serum samples (1 mL) was immunoadsorbed by adding 100 µL of a 75% (vol/vol) slurry of rabbit anti-ZPI polyclonal immunoglobulin (Ig)-G linked to Affigel-10 (2.5 mg/mL) and rocking the mixture for 1 hour. The Affigel was isolated by centrifugation (10 000g, 2 minutes) and washed 3 times with 1 mL HS. SDS-PAGE sample buffer (50 µL) was added to the Affigel pellet to extract the ZPI, and the Affigel was removed by centrifugation. Samples containing ZPI (5 µL) were separated by SDS-PAGE and analyzed by Western blotting with the use of mouse monoclonal anti-ZPI IgG (MC4249.2) or rabbit polyclonal anti-ZPI N-terminal peptide antibodies and alkaline phosphatase detection.11,16Other assays SDS-PAGE and ZPI functional assay were performed as previously described.10
Inhibition of factor Xa by ZPI Once a Ca++-dependent complex between PZ and factor Xa has formed at a phospholipid surface, the inhibition of factor Xa by ZPI occurs very rapidly (t1/2 less than 10 seconds). The requirement of PZ for ZPI-mediated factor Xa inhibition, however, is not absolute, and ZPI alone will inhibit factor Xa, although at a much slower rate (t1/2 = 210 minutes) (Figure 1). Heparin (0.25 U/mL) did not significantly affect ZPI inhibition of factor Xa in the presence of PZ (not shown) and enhanced ZPI inhibition of factor Xa in the absence of PZ to only a minor extent (factor Xa inhibition at 60 minutes: without heparin, 29 ± 10%; with heparin, 61 ± 8%).
As is typical for members of the serpin superfamily of proteinase
inhibitors, apparent proteolytic cleavage of ZPI occurs during its
inhibition of factor Xa (Figure 2). In
contrast to many other proteinase-serpin interactions, however, the
factor Xa-ZPI inhibitory complex is disrupted during SDS-PAGE (Figure 2), but can be detected by alkaline-PAGE (Figure
3). Under nondenaturing conditions, the
PZ-factor Xa-ZPI complex migrates as a smear. The apparently
clear area in the center of the smear in Figure 3 represents a staining
artifact. This peculiar migration pattern of the complex is most likely
due to variable loss of PZ and/or the dissociation of the factor
Xa-ZPI complex during the electrophoresis itself. The lack of
Ca++ and phospholipid during electrophoresis favors the
release of PZ, and the high pH (8.8) of the separation buffer reduces
the stability of the factor Xa-ZPI complex (unpublished
observations, 1999).
Previous work has shown that an altered form of recombinant ZPI, rZPI(Y387A) (in which tyrosine 387 is replaced with an alanine), does not inhibit factor Xa.11 This strongly implies that Y387 is the P1 residue at the reactive center of ZPI. To confirm this notion, the peptide (4.2 kd) released from ZPI following its interaction with factor Xa was isolated and sequenced (see "Materials and methods"). As anticipated, the N-terminal amino acid sequence of the peptide, SMPPVIKVDRPF, directly corresponded to the amino acid sequence of the ZPI molecule following Y387.11 ZPI inhibition of thrombin generation ZPI in the presence of PZ, phospholipids, and Ca++ is a potent inhibitor of factor Xa, and additional studies were undertaken to determine its effect on the prothrombinase complex (Figure 4). Preincubation (2 minutes) of PZ and ZPI with factor Xa, factor Va, phospholipids, and Ca++ dramatically reduced subsequent thrombin generation following the addition of prothrombin (Figure 4B). PZ and ZPI, however, failed to inhibit thrombin production in a similar mixture when prothrombin was present and factor Xa was added last to initiate the reaction (Figure 4B). In contrast, the combination of PZ and ZPI substantially delayed the initiation and reduced the ultimate rate of thrombin generation in the presence of prothrombin when factor V, rather than factor Va, was included in the reaction mixtures (Figure 4A). Presumably, under the latter conditions, PZ and ZPI are able to produce significant factor Xa inhibition prior to the generation of factor Va and the formation of the prothrombinase complex.
Reversibility of the factor Xa-ZPI complex The inability to detect a factor Xa-ZPI complex on SDS-PAGE suggested that the stability of the factor Xa-ZPI complex is considerably less than that of other proteinase-serpin interactions. To examine the dissociation of the factor Xa-ZPI complex, EDTA was added to mixtures incubated at 37° that contained factor Xa which had been inhibited more than 97% by ZPI in the presence of PZ, phospholipids, and Ca++. The chelation of Ca++ prevents factor Xa released from a factor Xa-ZPI complex from forming a subsequent, PZ-dependent interaction with additional ZPI molecules. EDTA treatment induced the progressive, though partial, return of factor Xa activity (Figure 5A). In a similar mixture that was not treated with EDTA, progressive cleavage of ZPI was observed with the ultimate return of some factor Xa activity (Figure 5A-B). The inclusion of factor Va in the mixture produced an earlier return of factor Xa activity and faster ZPI cleavage (Figure 5A,C). EDTA treatment prevented this progressive cleavage of ZPI (Figure 5D).
ZPI inhibition of factor XIa ZPI does not produce significant inhibition of thrombin, meizothrombin, factor VIIa, factor IXa, activated protein C, t-PA, u-PA, plasmin, trypsin, leukocyte elastase, chymotrypsin, or cathepsin G in the presence or absence of PZ, phospholipids, and Ca++.11 Additional studies showed that ZPI does not affect the activities of factor XIIa or kallikrein (not shown), but does inhibit factor XIa. Factor XIa inhibition by ZPI does not require the presence of PZ, phospholipids, or Ca++ and is not affected by the presence of high molecular weight kininogen (Figure 6, and not shown). Heparin (0.20 U/mL) increases the rate (t1/2 25 seconds vs 50 seconds) and the extent (99% vs 93%) of the factor XIa inhibition produced by ZPI (Figure 6).
Like the interaction of ZPI with factor Xa, the ZPI-factor XIa complex is not stable to SDS-PAGE, and the inhibition reaction produces cleavage of ZPI with a reduction in its apparent molecular weight from 72 kd to 68 kd (not shown). To determine the site in the reactive loop of ZPI that is involved in the inhibition of factor XIa, the peptide (4.2 kd) released following the interaction of ZPI with factor XIa was isolated following SDS-PAGE (see "Materials and methods). The N-terminal amino acid sequence of the peptide (SMPPVIKVDRPF) matched that of the peptide produced by the interaction of ZPI with factor Xa (above) and that following Y387 in the ZPI molecule.11 Moreover, the altered form of ZPI, rZPI(Y387A), does not inhibit factor XIa (not shown). Thus, the reactive center of ZPI that is involved in its inactivation of both factors Xa and XIa is Y387-S388 (P1-P1'). ZPI is consumed during coagulation The ZPI concentration in pooled normal human plasma was 3.84 µg/mL (53 nmol/L), but the serum produced following the induction of coagulation with kaolin, phospholipids, and CaCl2 contained little ZPI functional activity (less than 0.1 µg/mL). Western blot analysis of the plasma and serum produced by the induction of coagulation by kaolin, phospholipids, and Ca++ or tissue thromboplastin and Ca++ showed that ZPI was proteolytically cleaved during the clotting process with reduction in its apparent molecular weight from 72 kd to 68 kd (Figure 7A; lanes 1, 2, 5). On the basis of Western analysis using anti-peptide antibodies directed against the N-terminus of ZPI, this cleavage occurs at the C-terminus of the molecule and appears similar to the one that occurs during ZPI's inhibitory interactions with factor Xa and factor XIa (not shown). In additional experiments, proteolysis of ZPI was detected following the induction of coagulation with kaolin, phospholipids, and Ca++ in plasma deficient in factor VII or prothrombin, and following the induction of coagulation with tissue thromboplastin and Ca++ in plasma deficient in factors XII, XI, IX, VIII, or V or prothrombin (not shown). ZPI degradation was not detected when Taipan snake venom, which produces direct prothrombin activation, was used to initiate coagulation in normal plasma (not shown).
Treatment of normal plasma, but not factor XI-deficient plasma, with kaolin alone produced partial cleavage of ZPI (Figure 7A; lanes 3-4). Thus, factor XIa appears to be responsible at least in part for the proteolysis of ZPI that occurs when coagulation is induced through contact activation by kaolin. Cleavage of ZPI appears complete in normal plasma induced to clot with kaolin or tissue thromboplastin (Figure 7A; lanes 2, 5), whereas only partial cleavage of ZPI occurs in factor X-deficient plasma in which coagulation is initiated with kaolin, phospholipids, and Ca++, and no degradation of ZPI is seen in factor X-deficient plasma induced to clot with tissue thromboplastin and Ca++ (Figure 7B; lanes 2, 3). To further investigate the role of factor X and potentially PZ in the degradation of ZPI during coagulation, the XCP from Russell's Viper venom, phospholipids, and Ca++ were used to initiate coagulation in barium adsorbed plasma (BAP) with or without the addition of factor X and PZ (Figure 7B; lanes 4-6). No ZPI cleavage was detected in BAP alone, and only minimal ZPI cleavage occurred in BAP with added factor X. Complete ZPI cleavage, however, was found with the coagulation of BAP containing both factor X and PZ. In sum, the results suggest that factor Xa in concert with PZ is predominantly responsible for the consumption of ZPI that occurs when coagulation is initiated by means other than direct contact activation. With contact activation (eg, kaolin treatment), factor XIa also contributes significantly to ZPI degradation.
The inhibition of a proteinase by a serpin involves the
formation of an initial, reversible "encounter" interaction that
proceeds to 1 of 2 alternative fates: (1) the production of a stable
inhibitory complex or (2) an enzyme-substrate reaction with the
production of cleaved inhibitor and free enzyme.17 The
stable complex may also behave as a regular, albeit slow,
enzyme-substrate reaction with the ultimate production of cleaved
inhibitor and free enzyme. For certain enzyme-serpin interactions (eg,
chymotrypsin- The stability of the factor Xa-ZPI inhibitory complex appears to be
dramatically less than that of other enzyme-serpin complexes, eg, that
of thrombin-antithrombin. In contrast to the thrombin-antithrombin interaction, the factor Xa-ZPI complex is not stable to SDS-PAGE (Figure 2), although it can be detected in the less denaturing conditions of alkaline-PAGE (Figure 3). Dissociation of the
thrombin-antithrombin complex is very slow (approximately
2.5 × 10 PZ serves as a critical protein cofactor for the inhibition of factor Xa by ZPI, enhancing the rate of factor Xa inhibition more than 1000-fold. Such enhancement of a serpin's inhibitory action by a protein cofactor has been described previously. Thrombomodulin increases the rate of thrombin inhibition by protein C inhibitor approximately 140-fold.22 This effect of thrombomodulin appears to depend primarily on the protein-protein interaction between thrombin and thrombomodulin.22 Vitronectin also serves as a protein cofactor, increasing the rate of thrombin inhibition by plasminogen activator inhibitor-1 (PAI-1) about 200-fold.23-25 Vitronectin appears to produce this enhancement by binding PAI-1 and inducing a conformational change at its reactive center and through a protein-protein interaction with thrombin as well.25-28 PZ appears to bind factor Xa in a Ca++-dependent manner at phospholipid surfaces,10 and preliminary data show that a portion of plasma ZPI circulates in a complex with PZ.29 Thus, it is likely that the enhancement in ZPI-mediated factor Xa inhibition produced by PZ involves interactions of PZ with both factor Xa and ZPI. Besides inhibiting factor Xa in a PZ-, phospholipid-, and
Ca++-dependent fashion, ZPI produces rapid factor XIa
inhibition that does not require these cofactors. Whether this effect
of ZPI is physiologically relevant is not yet known, but studies
comparing the phenotypes of PZ- and
ZPI-gene-deleted mice may help address this issue.
It is important to note, however, that an apparent interaction between
factor XIa and ZPI is detectable in the plasma milieu, at least when
relatively large quantities of factor XIa are produced through
kaolin-induced contact activation (Figure 7A, lane 3; 7B, lane 2).
Under these in vitro conditions, therefore, ZPI appears to compete
effectively with the other factor XIa inhibitors (eg,
In the presence of PZ, ZPI inhibits not only factor Xa, but also factor Xa in the prothrombinase complex (Figure 4). PZ/ZPI inhibition of prothrombinase, however, is negated in the presence of plasma concentrations of prothrombin. Therefore, the anticoagulant action of PZ/ZPI must presumably precede the activation of factor V and/or perhaps follow the consumption of prothrombin at local sites. In reactions containing factor Xa, prothrombin, factor V, phospholipids, and Ca++, the combination of PZ and ZPI delays the initiation and the ultimate rate of thrombin generation (Figure 4). The results in this system that uses purified components are consistent with previous studies in an artificial plasma system that showed that the presence of PZ delays the initiation and reduces the rate and the final extent of thrombin generation when coagulation is initiated by small amounts of factor IXa.12 Moreover, the dampening of the coagulation process produced by PZ/ZPI is likely to be physiologically important as PZ deficiency dramatically enhances the thrombotic phenotype in mice with the factor VLeiden genotype.12
Submitted May 3, 2000; accepted June 21, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: George J. Broze Jr, Division of Hematology, Barnes-Jewish Hospital of St Louis, 216 South Kingshighway Blvd, St Louis, MO 63110; e-mail: broze{at}im.wustl.edu.
1.
Stenflo J, Fernlund P, Egan W, Roepstorff P.
Vitamin K dependent modifications of glutamic acid residues in prothrombin.
Proc Natl Acad Sci U S A.
1974;71:2730-2733
2.
Nelsestuen GL, Zytkovicz TH, Howard JB.
The mode of action of vitamin K: identification of gamma-carboxyglutamic acid as a component of prothrombin.
J Biol Chem.
1974;249:6347-6350
3.
Esmon CT, Suttie JW, Jackson CM.
The functional significance of vitamin K action: difference in phospholipid binding between normal and abnormal prothrombin.
J Biol Chem.
1975;250:4095-4099 4. Sejima H, Hayashi T, Deyashiki Y, Nishioka J, Suzuki K. Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Commun. 1990;171:661-668[Medline] [Order article via Infotrieve]. 5. Ichinose A, Takekya H, Espling E, Iwanaga S, Kisiel W, Davie EW. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun. 1990;172:1139-1144[Medline] [Order article via Infotrieve].
6.
Miletich JP, Broze GJ Jr.
Human plasma protein Z antigen: range in normal subjects and the effect of warfarin therapy.
Blood.
1987;69:1580-1586 7. McDonald JF, Shah AM, Schwalbe RA, Kisiel W, Dahlback B, Nelsestuen GL. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry. 1997;36:5120-5127[Medline] [Order article via Infotrieve]. 8. Prowse CV, Esnouf MP. The isolation of a new warfarin-sensitive protein from bovine plasma. Biochem Soc Trans. 1977;5:255-256[Medline] [Order article via Infotrieve]. 9. Broze GJ Jr, Miletich JP. Human protein Z. J Clin Invest. 1984;73:933-938.
10.
Han X, Fiehler R, Broze GJ Jr.
Isolation of a protein Z-dependent plasma protease inhibitor.
Proc Natl Acad Sci U S A.
1998;95:9250-9255 11. Han X, Huang Z-F, Fiehler R, Broze GJ Jr. Protein Z-dependent protease inhibitor is a serpin. Biochemistry. 1999;38:11073-11078[Medline] [Order article via Infotrieve].
12.
Yin Z-F, Huang Z-F, Cui J, et al.
Prothrombotic phenotype of protein Z deficiency.
Proc Natl Acad Sci U S A.
2000;97:6734-6738
13.
Broze GJ Jr, Majerus PW.
Purification and properties of human coagulation factor VII.
J Biol Chem.
1980;255:1242-1247 14. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994;5:551-559[Medline] [Order article via Infotrieve]. 15. Ausubel FM,Brent R,Kingston RE,,et al eds. Current Protocols in Molecular Biology. New York, NY: John Wiley & Sons; 1989:10.2.5-10.2.7. 16. Broze GJ Jr, Hickman S, Miletich JP. Monoclonal anti-human factor VII antibodies: detection in plasma of a second protein antigenically and genetically related to factor VII. J Clin Invest. 1985;76:937-946. 17. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-559[Medline] [Order article via Infotrieve].
18.
Shieh B-H, Potempa J, Travis J.
The use of
19.
Longstaff C, Gaffney PJ.
Serpin-serine protease binding kinetics: 20. Danielsson A, Bjork I. Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin. Biochem J. 1983;213:345-353[Medline] [Order article via Infotrieve]. 21. Han X, Fiehler RW, Broze GJ Jr. Characterization of protein Z-dependent protease inhibitor [abstract]. Blood. 1999;1:622a.
22.
Rezaie AR, Cooper ST, Church FC, Esmon CT.
Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex.
J Biol Chem.
1995;270:25336-25339
23.
Ehrlich HJ, Gebbink RK, Deijer J, Linders M, Preissner KT, Pannekoek H.
Alteration of serpin specificity by a protein cofactor: vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
J Biol Chem.
1990;265:13029-13035
24.
Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H.
On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Blood.
1991;78:1254-1261
25.
Naski MC, Lawrence DA, Moshert DF, Podor TJ, Ginsburg D.
Kinetics of inactivation of 26. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-A, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry. 1995;34:13833-13840[Medline] [Order article via Infotrieve].
27.
van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, Horrevoets AJG.
The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin.
Blood.
1997;90:1874-1882 28. van Meijer M, Stoop A, Smilde A, Preissner KT, van Zonneveld A-J, Pannekoek H. The composition of complexes between plasminogen activator inhibitor 1, vitronectin, and either thrombin or tissue-type plasminogen activator. Thromb Haemost. 1997;77:516-521[Medline] [Order article via Infotrieve]. 29. Tabatabai A, Fiehler RW, Broze GJ Jr. Oxidation of protein Z blocks its interaction with protein Z-dependent protease inhibitor [abstract]. Blood. 1999;94:457a. 30. Bouma BN, Meijers JC. Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis. Thromb Haemost. 1999;82:243-250[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  Z. Wei, Y. Yan, R. W. Carrell, and A. Zhou Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X Blood, October 22, 2009; 114(17): 3662 - 3667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. W. Gettins and S. T. Olson Exosite Determinants of Serpin Specificity J. Biol. Chem., July 31, 2009; 284(31): 20441 - 20445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Rezaie, J.-S. Bae, C. Manithody, S. H. Qureshi, and L. Yang Protein Z-dependent Protease Inhibitor Binds to the C-terminal Domain of Protein Z J. Biol. Chem., July 18, 2008; 283(29): 19922 - 19926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, Y. Tu, L. Lu, N. Lasky, and G. J. Broze Jr Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency Blood, May 15, 2008; 111(10): 4973 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Burggraf, B. Dorhofer, and B. Olgemoller Hybridization Probe Genotyping of the R67X Nonsense Polymorphism in the Protein Z-Dependent Protease Inhibitor Reveals a New R67Q Mutation Clin. Chem., July 1, 2007; 53(7): 1385 - 1387. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Abo and V. A. DeBari Laboratory Evaluation of the Antiphospholipid Syndrome Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Corral, R. Gonzalez-Conejero, J. M. Soria, J. R. Gonzalez-Porras, E. Perez-Ceballos, R. Lecumberri, V. Roldan, J. C. Souto, A. Minano, D. Hernandez-Espinosa, et al. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis Blood, July 1, 2006; 108(1): 177 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Heeb, K. M. Cabral, and L. Ruan Down-regulation of Factor IXa in the Factor Xase Complex by Protein Z-dependent Protease Inhibitor J. Biol. Chem., October 7, 2005; 280(40): 33819 - 33825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Rezaie, C. Manithody, and L. Yang Identification of Factor Xa Residues Critical for Interaction with Protein Z-dependent Protease Inhibitor: BOTH ACTIVE SITE AND EXOSITE INTERACTIONS ARE REQUIRED FOR INHIBITION J. Biol. Chem., September 23, 2005; 280(38): 32722 - 32728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Shoenfeld and M Blank Autoantibodies associated with reproductive failure Lupus, September 1, 2004; 13(9): 643 - 648. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. McQuillan, J. W. Eikelboom, G. J. Hankey, R. Baker, J. Thom, J. Staton, Q. Yi, and V. Cole Protein Z in Ischemic Stroke and its Etiologic Subtypes Stroke, October 1, 2003; 34(10): 2415 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Gris, C. Amadio, E. Mercier, G. Lavigne-Lissalde, H. Dechaud, M. Hoffet, I. Quere, J. Amiral, M. Dauzat, and P. Mares Anti-protein Z antibodies in women with pathologic pregnancies Blood, June 15, 2003; 101(12): 4850 - 4852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Crowther and J. G. Kelton Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System Ann Intern Med, January 21, 2003; 138(2): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Gris, I. Quere, H. Dechaud, E. Mercier, C. Pincon, M. Hoffet, M. Vasse, and P. Mares High frequency of protein Z deficiency in patients with unexplained early fetal loss Blood, April 1, 2002; 99(7): 2606 - 2608. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, without PZ or ZPI; 
, ZPI with
PZ; and 
, ZPI without PZ.
, with PZ,
without ZPI; 
, without PZ, with ZPI; 
, with PZ, with ZPI; 
,
factor Xa preincubated with PZ, ZPI, factor Va, phospholipids,
and CaCl2 prior to the addition of prothrombin.
, factor Xa
alone; 
, factor XIa
with heparin.
2-antiplasmin), it has been shown that the
inhibitory enzyme-serpin complex can dissociate to give active
inhibitor and free enzyme.
6 seconds